ApprovedFDA approval

Beqalzi (sonrotoclax)

BeOne Medicines (ONC)

Marketer take

A BCL2 inhibitor for mantle cell lymphoma after a BTK inhibitor, a late-line niche where Jaypirca and CAR-T already compete, so lymphoma-focused hematologist-oncologists are the core audience.

Sponsor company
BeOne Medicines (ONC)
Indication
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor
Therapeutic area
Oncology, Hematology
Event
FDA approval
Date
May 13, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move